[Influence of smoking on the efficacy of immunotherapy in advanced lung cancers].

IF 0.5 4区医学 Q4 RESPIRATORY SYSTEM

Revue des maladies respiratoires Pub Date : 2025-05-14 DOI:10.1016/j.rmr.2025.04.003

F Biney, É Giroux-Leprieur, C Daniel, P Du Rusquec, J B Auliac, J B Assié, S Anane-Abrous, C Chouaid

{"title":"[Influence of smoking on the efficacy of immunotherapy in advanced lung cancers].","authors":"F Biney, É Giroux-Leprieur, C Daniel, P Du Rusquec, J B Auliac, J B Assié, S Anane-Abrous, C Chouaid","doi":"10.1016/j.rmr.2025.04.003","DOIUrl":null,"url":null,"abstract":"Introduction: Lung cancer is the leading cause of death worldwide. It occurs mainly in smokers, but also in 25% of cases in non-smokers. As regards metastatic stages, while immunotherapy has led to improved overall survival, smoking status may potentially influence its effectiveness. The objective of this study was to analyze its effectiveness as first-line treatment for advanced non-small cell lung cancers (NSCLC) according to patient smoking status.Method: This retrospective study covers all patients with stage IV NSCLC treated with first- line immunotherapy, alone or in combination, between January 2018 and 2019, in three Ile de France centers. The primary and secondary endpoints were, respectively, overall survival and progression-free survival, according to smoking status.Results: The analysis included 105 patients (66.7% men) of whom 38% were active smokers and 9.5% non-smokers, with adenocarcinoma in 65.7% of cases. Median OS and PFS were 17, 23.2, and 24.9 months and 4.9, 7.6, and 4 months for smokers, ex-smokers, and non-smokers respectively, without significant differences.Conclusion: In this study, smoking status did not seem to modify the effectiveness of immunotherapy. Studies on a larger population are called for.","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue des maladies respiratoires","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.rmr.2025.04.003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lung cancer is the leading cause of death worldwide. It occurs mainly in smokers, but also in 25% of cases in non-smokers. As regards metastatic stages, while immunotherapy has led to improved overall survival, smoking status may potentially influence its effectiveness. The objective of this study was to analyze its effectiveness as first-line treatment for advanced non-small cell lung cancers (NSCLC) according to patient smoking status.

Method: This retrospective study covers all patients with stage IV NSCLC treated with first- line immunotherapy, alone or in combination, between January 2018 and 2019, in three Ile de France centers. The primary and secondary endpoints were, respectively, overall survival and progression-free survival, according to smoking status.

Results: The analysis included 105 patients (66.7% men) of whom 38% were active smokers and 9.5% non-smokers, with adenocarcinoma in 65.7% of cases. Median OS and PFS were 17, 23.2, and 24.9 months and 4.9, 7.6, and 4 months for smokers, ex-smokers, and non-smokers respectively, without significant differences.

Conclusion: In this study, smoking status did not seem to modify the effectiveness of immunotherapy. Studies on a larger population are called for.

查看原文本刊更多论文

吸烟对晚期肺癌免疫治疗效果的影响

肺癌是世界范围内死亡的主要原因。主要发生在吸烟者中，但也有25%的病例发生在非吸烟者中。至于转移期，虽然免疫疗法提高了总体生存率，但吸烟状况可能会影响其有效性。本研究的目的是根据患者吸烟状况分析其作为晚期非小细胞肺癌（NSCLC）一线治疗的有效性。方法：这项回顾性研究涵盖了2018年1月至2019年3个法兰西岛中心接受一线免疫治疗的所有IV期非小细胞肺癌患者，单独或联合。根据吸烟状况，主要终点和次要终点分别是总生存期和无进展生存期。结果：纳入105例患者（66.7%为男性），其中38%为活跃吸烟者，9.5%为非吸烟者，65.7%为腺癌。吸烟者、戒烟者和非吸烟者的中位OS和PFS分别为17、23.2和24.9个月，分别为4.9、7.6和4个月，无显著差异。结论：在本研究中，吸烟状况似乎并未改变免疫治疗的有效性。需要对更大的人群进行研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revue des maladies respiratoires 医学-呼吸系统

CiteScore

1.10

自引率

16.70%

发文量

168

审稿时长

4-8 weeks

期刊介绍： La Revue des Maladies Respiratoires est l''organe officiel d''expression scientifique de la Société de Pneumologie de Langue Française (SPLF). Il s''agit d''un média professionnel francophone, à vocation internationale et accessible ici. La Revue des Maladies Respiratoires est un outil de formation professionnelle post-universitaire pour l''ensemble de la communauté pneumologique francophone. Elle publie sur son site différentes variétés d''articles scientifiques concernant la Pneumologie : - Editoriaux, - Articles originaux, - Revues générales, - Articles de synthèses, - Recommandations d''experts et textes de consensus, - Séries thématiques, - Cas cliniques, - Articles « images et diagnostics », - Fiches techniques, - Lettres à la rédaction.